Ocular Toxicity

• TIVDAK caused changes in the corneal epithelium and conjunctiva resulting in changes in vision, including severe vision loss, and corneal ulceration. 
• Conduct an ophthalmic exam including an assessment of ocular symptoms, visual acuity, and slit lamp exam of the anterior segment of the eye prior to initiation of TIVDAK, prior to every cycle for the first nine cycles, and as clinically indicated.
• Adhere to premedication and required eye care before, during, and after infusion.
• Withhold TIVDAK until improvement and resume, reduce the dose, or permanently discontinue, based on severity.